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Abstract: The bone morphogenetic proteins (BMPs), a subgroup of the transforming growth factor-β
(TGF-β) superfamily, are involved in multiple biological processes such as embryonic development
and maintenance of adult tissue homeostasis. The importance of a functional BMP pathway is
underlined by various diseases, including cancer, which can arise as a consequence of dysregulated
BMP signaling. Mutations in crucial elements of this signaling pathway, such as receptors, have
been reported to disrupt BMP signaling. Next to that, aberrant expression of BMP antagonists could
also contribute to abrogated signaling. In this review we set out to highlight how BMP antagonists
affect not only the cancer cells, but also the other cells present in the microenvironment to influence
cancer progression.
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1. Introduction
The bone morphogenetic proteins (BMPs) belong to the transforming growth factor (TGF)-β
superfamily, which also comprises the TGF-βs, activins, nodal, inhibins and myostatin [1]. While BMPs
were first discovered because of their ability to promote endochondral bone growth, hence the name,
BMP action is now known to contribute to several crucial biological processes throughout the entire
body ranging from embryonic development and patterning to adult tissue homeostasis and control of
stem cells and their niches [2]. Since BMPs are implicated in such diverse biological processes, it has
been suggested that their name should be changed to body morphogenic proteins [2].
Canonical BMP signaling (Figure 1) takes places when BMP ligands interact with the type I and
type II BMP receptors, inducing heteromeric complex formation of the two different receptor types.
The constitutively active type II receptors then phosphorylate the type I receptors, which phosphorylate
the SMAD proteins SMAD1, SMAD5 and SMAD8 [3]. The activated SMAD complex binds SMAD4
after which it is translocated to the nucleus where they regulate transcription of BMP target genes.
In addition, non-canonical BMP signaling occurs via mitogen-activated protein kinases (MAPKs) in
a SMAD-independent manner (Figure 1) [3]. BMP pathway activity is dependent on tissue specific
BMP ligand expression and the presence of BMP receptors on the cells [4]. Additionally, local BMP
bioavailability and subsequent BMP signaling is further regulated by a group of molecules which bind
and sequester BMPs, collectively called BMP antagonists. By binding to the BMPs, the BMP ligands
can no longer bind to their receptor and BMP signaling is prevented [5]. These interactions between the
BMPs and their respective antagonists are necessary to govern the BMP signaling amplitude needed
for the biological processes to take place successfully [6]. In vivo, the outcome of BMP signaling in
relation to the BMP antagonists is complex. Some antagonists have been shown to inhibit BMPs when
present in high concentrations, while stimulating BMP activity when present at low concentrations [4].
Besides interacting with BMPs, the antagonists have also been shown to interact with one another.
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The binding of one antagonist to another type of antagonist can potentiate the effect of the antagonist
or inhibit it. To make antagonist-mediated BMP signaling even more complex, there is interplay with
several other signaling pathways such as Wnt, Notch, Sonic hedgehog (Shh) and the fibroblast growth
factor (FGF) pathway [5]. Additionally, besides directly inhibiting BMP signaling, BMP antagonists
have also been shown to elicit their effect through modulation of these other pathways [7]. This makes
the outcome of BMP signaling an intricate process that is highly dependent on the cellular context.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 2 of 17 
 
the outcome of BMP signaling in relation to the BMP antagonists is complex. Some antagonists have 
been shown to inhibit BMPs when present in high concentrations, while stimulating BMP activity 
when present at low concentrations [4]. Besides interacting with BMPs, the antagonists have also been 
shown to interact with one another. The binding of one antagonist to another type of antagonist can 
potentiate the effect of the antagonist or inhibit it. To make antagonist-mediated BMP signaling even 
more complex, there is interplay with several other signaling pathways such as Wnt, Notch, Sonic 
hedgehog (Shh) and the fibroblast growth factor (FGF) pathway [5]. Additionally, besides directly 
inhibiting BMP signaling, BMP antagonists have also been shown to elicit their effect through 
modulation of these other pathways [7]. This makes the outcome of BMP signaling an intricate 
process that is highly dependent on the cellular context. 
 
Figure 1. A schematic representation of the bone morphogenetic proteins (BMP) signaling cascade. 
BMP antagonists are important regulators of BMP signaling amplitude as they directly bind BMPs, 
thereby preventing them from interacting with the receptors. 
2. Classification of BMP Antagonists 
Presently, multiple BMP antagonists have been reported. No significant similarities are found 
when amino acid sequences are compared (Figure 2). That the antagonists all belong to a single family 
becomes more clear towards the C terminus or cystine-knot domain of the proteins [8]. Most BMP 
antagonists are subclassified into subgroups based on their cystine-knot size [9]. These cystine-knots 
are functional motifs that determine how the peptides are folded and which hydrophobic residues, 
needed for protein–protein interaction, are exposed [10]. In the subclassification system based on the 
cystine-knot size, most of the antagonists are categorized in three main subgroups. The differential 
screening selected gene aberrative in neuroblastoma (DAN) subfamily, consisting of DAN, the 
Cerberus homologue Cer1, Coco, protein related to Dan and Cerberus (PRDC), Gremlin, uterine 
sensitization-associated gene 1 (USAG-1) and Sclerostin, possess a cystine-knot with eight cysteine 
residues making up the ring of the knot (Figure 2) [9]. The second subgroup consists of twisted 
gastrulation (TSG) only which has a nine-cysteine ring. Chordin and Noggin make up the third 
subgroup and have ten cysteine residues in the cystine-knot [9]. Many of the antagonists form 
homodimers but some are reported to be monomers (Figure 2) [4]. 
Figure 1. A schematic representation of the bone morphogenetic proteins (BMP) signaling cascade.
BMP antagonists are important regulators of BMP signaling amplitude as they directly bind BMPs,
thereby preventing them from interacting with the receptors.
2. Classification of BMP Antagonists
Presently, multiple BMP antagonists have been reported. No significant similarities are found
when amino acid sequences are compared (Figure 2). That the antagonists all belong to a single
family becomes more clear towards the C terminus or cystine-knot domain of the proteins [8].
Most BMP antagonists are subclassified into subgroups based on their cystine-knot size [9]. These
cystine-knots are functional motifs that determine how the peptides are folded and which hydrophobic
residues, needed for protein–protein interaction, are exposed [10]. In the subclassification system
based on the cystine-knot size, most of the antagonists are categorized in three main subgroups.
The differential screening selected gene aberrative in neuroblastoma (DAN) subfamily, consisting of
DAN, the Cerberus homologue Cer1, Coco, protein related to Dan and Cerberus (PRDC), Gremlin,
uterine sensitization-associated gene 1 (USAG-1) and Sclerostin, possess a cystine-knot with eight
cysteine residues making up the ring of the knot (Figure 2) [9]. The second subgroup consists of
twisted gastrulation (TSG) only which has a nine-cysteine ring. Chordin and Noggin make up the
third subgroup and have ten cysteine residues in the cystine-knot [9]. Many of the antagonists form
homodimers but some are reported to be monomers (Figure 2) [4].
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weak interactions with an antagonist are shown in red. (This figure only shows the most well-known
and studied antagonists).
3. BMP Antagonists and Cancer
In adult tissue, it is increasingly acknowledged that the subversion of the balance between
BMPs and their antagonists may underlie several diseases, including cancer. To understand how
BMP antagonists could contribute to oncogenesis, some background on how BMP agonists exert
their function is needed. BMPs are thought to play a tumor-suppressing role as BMPs induce
cell differentiation and apoptosis and therefore loss of a crucial signaling component could result
in increased cell proliferation [11]. However, it seems like their role, tumor promoting or tumor
suppressing, depends on the specific BMP ligand, the cancer type and the tumor stage. Multiple studies,
both in animal models and in humans, have indeed demonstrated a strong relationship between
epithelial loss of functional BMP receptors and the initiation or progression of specific cancers [12].
Theoretically, BMP antagonists could be expected to play a tumor-promoting role as BMPs induce
cell differentiation and apoptosis and BMP antagonists could inhibit BMPs from doing so. The BMP
pathway has been implicated in various stages of carcinogenesis in multiple cancers [13]. Many studies
have reported involvement of the pathway in the proliferation, migration and invasion of epithelial
cancer cell . Next to i creas d expression of matrix metalloproteinases and integrins, which contribute
to the increased migration and invasion apac y of the cancerous cells, BMPs have also b en shown to
induce epithelial to mesenchyma transition [13]. These re all processes that help the tumor cells to
successfully metastasize.
A very illustrative example of how deregulation of BMP signaling could contrib te to
carcinogenesis can be found in the intestines. The intestines are well known for their high cellular
turnover [14]. In humans, it takes around 4–7 days to completely replenish the epithelial cells
composing the crypt-villus axis [15]. Cell renewal is tightly regulated by various signaling pathways
with the Wnt and BMP pathway being key players [15,16]. While Wnt signaling drives cell proliferation
of the stem cells and transient amplifying cells in the crypts, BMP signaling becomes more prominent
in the top part of the crypt-villus axis. Here it makes sure that cells differentiate and commit to a certain
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cell lineage, thereby losing their proliferative features [15,16]. Individuals with juvenile polyposis
syndrome (JPS) are carriers of mutations in crucial components of the BMP pathway such as the
BMP receptor 1a (BMPR1a) or the downstream signaling molecule SMAD4. Individuals carrying
these mutations develop multiple polyps throughout the gastrointestinal tract from a very young age.
The discovery of the relationship between the loss of BMP pathway components and JPS led to the
consideration that BMP inactivation could be involved in sporadic colorectal cancers (CRC) as well.
Indeed, the BMP pathway was found to be abrogated in a large number of sporadic CRC cases [17].
In the same way, dysregulation of BMP antagonists may likewise contribute to oncogenesis.
An in vivo study with transgenic mice overexpressing Noggin showed that overexpression resulted
in a loss of the normal crypt-villus architecture along with de novo crypt formation and neoplasia.
This is probably due to Noggin antagonizing BMP signaling and therefore inhibiting differentiation
and apoptosis of epithelial cells. Interestingly, the authors state that the intestinal changes in these
mice phenocopy the histopathology seen in intestines of patients with JPS [18]. These data illustrate
how the overexpression of a BMP antagonist can result in a similar outcome compared to when a
crucial factor required for BMP signaling is lost. In practice, upregulation of a BMP antagonist to
overcome BMP signaling is rarely seen in cancer. Most studies have rather reported downregulation of
BMP antagonists.
4. The Tumor and Its Microenvironment
While a relatively large amount of attention has been given to aberrant BMP signaling in cancer
cells, very little attention has been given to the other cells present within the tumor. The role of the
tumor microenvironment is increasingly receiving recognition in cancer progression. The bidirectional
exchange of information between epithelial cells and their microenvironment is not only crucial for the
maintenance of adult tissue homeostasis but also determines the rate and aggressiveness with which
cancers progress. For example, our group recently demonstrated that fibroblasts upregulate BMP2
as a reaction to tumor secreted tumor necrosis factor-related apoptosis inducing ligand (TRAIL) [19].
Fibroblast secreted BMP2 in turn stimulated migration, invasion and metastasis formation in the
liver. The impact of non-epithelial parts of the tumor, also called “stroma” on cancer initiation and
development can no longer be denied as studies suggest that stroma even has the ability to “normalize”
aggressive oncogenic mutations in epithelial cells to such an extent that these cells will not evolve
into a tumor [20–22]. The cancer associated fibroblasts (CAFs), endothelial cells and immune cells
that compose the stromal compartment, all respond to or secrete BMP antagonists (Figure 3). In the
sections below, we will discuss some of the main findings per cell type and how they are affected by
BMP antagonists. It is noteworthy that although many BMP antagonists have been identified, only a
few are being researched in the context of cancer: Noggin, Gremlin and, to a lesser extent, Chordin,
Sclerostin and PRDC.
4.1. The Cancer Cells
It is well acknowledged that carcinomas are formed due to an accumulation of mutations in cells
of epithelial origin [23]. These mutations allow cells to proliferate rapidly. Additional mutations,
both on genetic and epigenetic level, in these cancer cells drive tumor progression as new traits are
acquired that cause the tumor to behave more aggressively. Multiple studies, both in animal models
and in humans, have demonstrated a strong relationship between the loss of functional BMP receptors
and the initiation or progression of specific cancers [12]. However, when it comes to the role of BMP
antagonists in cancer progression, conflicting results have been reported. While some studies reported
that these antagonists have a growth inhibiting effect and are upregulated in some cancers, others
showed the opposite. An overview of these studies can be found in Table 1.
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1 Gremlin
Desp te th se co flictin data there a e some good indications th t BMP antagonists re involved
in cancer progression. T e mos compelling evi e ce for the ro e of a BMP antagonist, Gr mlin in
this case, in human ca cer development comes from a tudy in wh ch a 40 kb duplication upstream
GREM1 was analyzed. This duplication wa found in a large family of Ashkenazi Jews suffering from
hereditary mixed polyposis syndrome (HMPS) and the GREM1 locus was attributed to b causal for the
histopathology [24]. Additionally, transcription enhancer elements encoded by genes present within
this duplication fou d in HMPS p tients w re sh wn to interact in vivo with the GREM1 prom tor
to further enhance gene expression [24]. Multiple GREM1 duplications have been reported since
and overexpression of GREM1 is thought to lead to polyp formation and cancer in the intestine [25].
This seems to occur via the formation of ectopic crypts thereby distorting the normal crypt-villus
architecture. This presumably exposes stem cells within the ectopic crypts to the toxic environment
outside the true crypt-base, thereby predisposing them to cancer. The stem cell niche seems to be
defined by high levels of GREM1 that are normally only expressed by the pericryptal fibroblasts.
Ectopic expression of high levels of GREM1 by epithelial cells in the villus leads to cells halfway up
the villus behaving as stem cells and forming ectopic crypts. GREM1 overexpression could therefore
create an environment that allows for maintenance of stemness and an increase in the number of cells
with the ability to proliferate.
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4.1.2. Noggin
The link between Noggin and cancer has been mainly investigated in cancers metastasizing to the
bone. It has been shown that prostate and non-small cell lung cancer (NSCLC) cell lines overexpressing
Noggin show decreased growth/expansion capabilities in a xenograft mouse model [26,27]. In addition,
several in vitro studies have found Noggin to be downregulated in cancer cell lines of different
origin and it has the ability to counteract the tumorigenic processes initiated by BMPs, for example,
proliferation, migration, etcetera [28–32]. Although these functional studies provide important
information regarding the role of Noggin in tumor progression, it should be noted that the models
employed a non-endogenous Noggin overexpression approach and do not provide direct evidence
that these mechanisms are also exploited by mammalian (cancer) cells.
4.1.3. Others
Compared to Noggin and Gremlin, substantially less research has been conducted on the role
of Chordin and Sclerostin. Chordin was found to be downregulated in ovarian tumors compared
to both normal tissue and, more specifically, the epithelial lining covering the surface of the ovaries.
It was further shown that re-expression of Chordin in ovarian cancer cell lines decreased migration
and invasion [33]. Sclerostin, encoded by the sclerostin domain-containing protein 1 (SOSTDC1)
gene, was recently found to be negatively correlated with the aggressiveness of non-small cell lung
cancer and gastric cancer as lower expression was observed in metastases compared to primary
tumors [34,35]. PRDC, a GREM1 homologue showing strong resemblance to Noggin and Chordin as
well, was recently connected to cancer progression [36]. PRDC was found to be downregulated in a
microarray gene expression analysis performed on five endometrial cancer (EC) specimens compared
to normal leiomyoma tissue. In addition, the presence of PRDC was found to inhibit proliferation of
the EC cancer cell lines Ishikawa and HEC-1A in a dose dependent manner [37]. An opposing role
for PRDC in cancer progression was reported in a study on gastric cancer, where it was shown to be
upregulated. Silencing of PRDC resulted in decreased proliferation, migration and invasion in vitro
while preventing tumor formation and lymph node metastasis in vivo [38]. Taken together the role of
PRDC in tumor progression remains unclear.
The conflicting data, when it comes to the effect of BMP antagonists on cancer cells, could be
partially explained by the genetic makeup of the cancer cells. At first it seems beneficial for cancer
cells to inactivate the BMP pathway to render them non-susceptible to differentiation and apoptosis.
However, several BMPs such as BMP2 and BMP4, have been found to be upregulated in multiple
cancers where they contribute to migration, invasion and dissemination [19,39–41]. While canonical
BMP signaling results in cell differentiation and apoptosis, non-canonical (non-SMAD4) signaling
leads to activation of phosphoinositide 3-kinases (PI3Ks), MAPKs and the Ras homolog (Rho) family of
GTPases [13]. These pathways are generally linked to the induction of angiogenesis, cell proliferation,
cell survival and metastasis in various cancer types [31]. So, while cancer cells would generally benefit
from abrogating BMP signaling, cancer cells with a non-functional canonical pathway (e.g., due to
loss of SMAD4) could profit from active BMP signaling. Indeed, some studies have shown that BMP
signaling changes from tumor suppressing to tumor promoting upon loss of SMAD4 [41–43]. Therefore,
the genetic makeup, or mutanome of the cancer cells, seems to add a layer of complexity to an already
complex topic.
A second layer of complexity is the BMP antagonists themselves. We could speculate that the
effect of the antagonists will be dependent on the mutation profile as well, so that cancer cells that
downregulate the antagonists could also be the cancer cells that flourish in the presence of BMPs due
to non-canonical signaling. The cancer cells that upregulate the BMP antagonists (by themselves or by
instructing the microenvironment) could be the cells with intact canonical BMP signaling. These are,
unfortunately, questions we cannot answer yet due to the complexity of processes involved in tumor
development and the heterogeneity between cancer types and the different cancer cell lines. These
ideas also assume that the BMP antagonists carry out their effect exclusively via the sequestering of
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BMP ligands. While this could indeed be true for many of the studies, angiogenesis resulting from
the binding of Gremlin to vascular endothelial growth factor (VEGF) receptor 2 (discussed later),
proves that this is not necessarily the case. It would be very valuable if researchers in the future could
ascertain whether BMP antagonists act via their effect on sequestering BMPs or independent from
them. This could greatly increase our insights into the role of BMP antagonists.
4.2. The Cancer Associated Fibroblasts
A major constituent of the stroma are CAFs that arise from normal resident fibroblasts that become
“activated” by cytokines in the tumor microenvironment. Furthermore, it is thought that CAFs can
also be derived from bone marrow-derived mesenchymal cells, epithelial to mesenchymal transition
(EMT) or smooth muscle cells/pericytes from the vasculature. During recent years, the enormous
heterogeneity within the phenotype and function of the CAF population has been increasingly unveiled.
While CAFs were thought to always express α-smooth muscle actin (α-SMA), fibroblast activation
protein (FAP), platelet-derived growth factor (PDGF) receptor α/β and cluster of differentiation 90
(CD90), recently subsets of CAFs negative for these markers have been identified, which execute
different roles (e.g., in cancer, inflammation and homeostasis) [44]. It is only recently that a consensus on
the nomenclature and functioning of CAFs has been proposed [45]. Below we will discuss the studies
regarding BMP antagonists and fibroblasts. Since fibroblasts are the largest stromal constituent, this
section will also include studies in which the total stroma was studied. If not clearly stated in the study,
we will refer to fibroblasts when explicitly mentioned and refer to stroma when insufficiently defined.
4.2.1. Gremlin
While the data discussed previously illustrate how the epithelial cancer cells themselves are affected
by their own aberrant expression of BMP antagonists, the following studies outline situations in which
aberrant BMP antagonist production could affect the epithelial cells in a paracrine fashion. A study
that adapted a genomic approach was among the first studies supporting a possible contribution of
stromal secreted BMP antagonists in cancer progression [46]. To determine which factors are expressed
differently by stromal cells in the basal cell carcinoma (BCC) microenvironment and normal skin, gene
expression profiles were generated from primary stromal cell cultures. GREM1 was not only found to
be upregulated by stromal cells isolated from BCC, but also for a number of other cancer types such as
prostate, colon, pancreas and esophageal cancer [46]. These antagonists produced and secreted by the
stromal cells could possibly support cell growth and inhibit both differentiation and apoptosis.
While the upregulation of Gremlin suggests a possible involvement in the pathology of a disease,
further evidence is required to draw conclusions about a causative or supporting role. Two studies have
investigated the prognostic significance of stromal Gremlin expression in cancer progression [47,48].
Stromal Gremlin expression in colorectal cancer, as determined by GREM1 in situ hybridization,
was found to be associated with a less advanced cancer stage, decreased lymphovascular invasion and
improved recurrence-free and overall survival [47]. However, in breast cancer the opposite has been
reported. There Gremlin expression was found to predict worse clinical outcomes [48]. The beneficial
prognostic traits associated with stromal Gremlin expression in colorectal cancer seems counterintuitive
considering the association found between stromal Gremlin expression and induction of EMT as
implicated in generating cancer stem cells (CSC) and the development of metastatic cancer [49,50].
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Table 1. Overview of studies concerning the role of BMP antagonists in cancer.
Antagonist Model Used Organ Finding Effect on Tumor References
Chordin Ovarian carcinoma cell lines BG1 and PEO14 and human specimens Ovaries Chordin downregulated in tumors and cancer cell lines Suppressing Moll et al. 2006 [33]
Gremlin
Basal cell carcinomas Skin Increased tumor cell proliferation Promoting Sneddon et al. 2006 [46]
Human specimens Various Increased GREM1 expression was found in uterine, ovary, lung, kidney,colon, pancreas and breast carcinomas Promoting Namkoong et al. 2006 [51]
Clear cell renal cell carcinomas Kidney GREM1 promoter methylation correlates with increased malignancy andactive angiogenesis Suppressing
van Vlodrop et al. 2010
[52]
Human hereditary mixed polyposis (HMPS) syndrome specimens Intestines Mutation drives GREM1 expression Promoting Jaeger et al. 2012 [24]
Primary mesothelioma cells Mesothelium shRNA mediated downregulation of GREM1 inhibits cell growth andrenders susceptibility to paclitaxel Promoting Tamminem et al. 2013 [53]
Pancreatic neuroendocrine tumors Pancreas High Gremlin expression identified as a favorable prognostic marker Suppressing Chen et al. 2013 [54]
Primary Glioma cell lines Brain Increased proliferation and progression from cell cycle arrest Promoting Yan et al. 2014 [55]
Human mesothelioma cell lines with Gremlin overexpression Mesothelium Overexpression increases tumor vascularization with an increasedchance to metastasize Promoting Yin et al. 2017 [56]
4T1 mouse mammary tumor model, breast cancer cell lines 66cl4 and
67NR and human specimens Breast
GREM1 associated with metastases and worse prognosis in estrogen
receptor-negative breast cancer patients Promoting Neckmann et al. 2019 [57]
PRDC
Human endometrial cancer (EC) specimens and Ishikawa and
HEC-1A EC cell lines Endometrium
PRDC was found to be downregulated in ECs and inhibited proliferation
of cancer cells Suppressing Tsubamoto et al. 2016 [37]
In silico analysis on gastric cancer microarray expression data and in
vitro and in vivo experiments with the gastric cancer cell line
MNK-45 with a PRDC downregulation
Stomach
PRDC was found to be upregulated in gastric cancer. Silencing of PRDC
in MNK-45 resulted in vitro in decreased proliferation, migration
and invasion. in vivo, tumor formation and lymph node metastasis
was inhibited.
Promoting Ran et al. 2019 [38]
Noggin
Noggin-overexpression mouse Intestines De novo crypt and polyp formation Promoting Haramis et al. 2004 [18]
Osteolytic PC-3 cancer cells with Noggin overexpression Prostate Inhibition of PC-3 cell expansion Suppressing Feeley et al. 2006 [26]
B16-F1 melanoma cell line growth in the chick embryonic optic cup Skin Decreased invasive growth Suppressing Busch et al. 2007 [58]
Melanoma cell lines Skin Expression of Noggin renders the cells less/non-susceptible forBMP7-growth inhibiting effects Promoting Hsu et al. 2008 [59]
A549 non-small cell lung cancer cell line with Noggin overexpression Lung Growth inhibition Suppressing Feeley et al. 2009 [27]
Keratin14-driven Noggin overexpression mouse Skin Development of spontaneous hair-follicle derived tumors Promoting Sharov et al. 2009 [60]
Osteolytic PC-3 cancer cells retrovirally transduced with Noggin Prostate Decreased bone loss and smaller tumors Suppressing Virk et al. 2009 [61]
Osteolytic PC-3 cancer cells transduced with Noggin-shRNA Prostate Decreased growth of cancer cells Promoting Secondini et al. 2011 [62]
Breast cancer cell lines and human specimens Breast Increased expression in metastatic lesions and Noggin overexpressionfacilitates bone colonization Promoting Tarragona et al. 2012 [63]
Sclerostin
Human non-small cell lung cancer specimens and cell lines Lung SOSTDC1 expression associated with a better survival and reduced cellproliferation of cell lines Suppressing Liu et al. 2016 [35]
Human gastric cancer specimens Intestines Lower SOSTDC1 expression in primary tumors compared to normaltissue and in metastases compared to primary tumors. Suppressing Cui et al. 2019 [34]
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Interestingly, multiple studies have shown that Gremlin expression is causally associated with
both the presence and maintenance of mesenchymal characteristics, not only during development but
also in cancer stem cell niches [50,53,64,65]. In one particular study, Gremlin and α-SMA expressing
CAFs in colorectal cancers were observed near the tumor invasive front where tumor cells showed
nuclear accumulation of β-catenin and the loss of the tight junction protein occludin [66]. Gremlin
expression was found to be associated with the occurrence of carcinoma cells with an EMT phenotype
near the invasive front. Additional in vitro experiments in which CRC cell lines were stimulated with
Gremlin showed indications of EMT as defined by downregulation of E-cadherin, and increased Snail
and N-cadherin expression [66]. It is well known that TGF-β, often found to be upregulated in the
tumor stroma, can induce EMT and that BMP signaling could oppose this process [67]. These results
together support the existence of a paracrine interaction between CAFs and cancer cells in which
Gremlin could be involved in tumor progression, either by shaping the microenvironment to support
the tumor cells or by facilitating processes such as EMT.
4.2.2. Noggin
Less convincing roles are found for fibroblast-derived Noggin. However, one study reported that
xenografts of a prostate cancer cell line (LNCaP) upregulated Nog in the stromal compartment of mice
overexpressing Shh using species specific primers [68]. While not showing a direct causal relationship,
this study does show that cancer cells could have the ability to instruct the stroma to produce certain
BMP antagonists, which in turn could favor tumor growth.
Expression of BMP antagonists by the tumor stroma could partially explain the conflicting data
concerning the role of BMP antagonists in cancer. Could the downregulation of BMP antagonists,
often observed in human cancer samples, be regulated by stromal cells to halt cancer cell proliferation?
Is this normalizing cue finally misused by the continuously evolving cancer cells later in tumor
progression (possibly due to mutations in the BMP pathway) to facilitate tumor growth? In the light of
the CAF heterogeneity, it would be valuable to investigate which CAF subset(s) are the main producers
of BMP antagonists. Could it be the “tumor restricting” CAF-populations trying to slow down tumor
progression or the “tumor promoting” CAFs instructed by the cancerous cells? The steady increase in
the amount of research conducted on CAFs might in the future provide us an answer that will also
help us understand why a favorable prognosis was reported in some studies, but a poor prognosis was
found in others.
4.3. The Endothelial Cells
In normal tissue endothelial cells are found in a quiescent state but tumor growth and its
dissemination are heavily dependent on tumor vascularization [69]. If not sufficiently formed this can
slow down the rate by which the tumor grows and progresses [69]. The “angiogenic switch” is defined
as the moment in which there is a transition in the vasculature from a quiescent state to a proliferative
state, thereby inducing angiogenesis [70]. This process has been shown to be promoted and influenced
by the recruitment of innate immune cells (discussed later) and CAFs [70].
Gremlin
Apart from functioning as a BMP antagonist, Gremlin has been shown to have its own intrinsic
signaling pathway that is BMP ligand independent. Recombinant Gremlin was found to bind
with high affinity to endothelial cells in vitro, activating the intracellular signaling pathways
extracellular-signal-regulated kinase (ERK), paxillin and focal adhesion kinase (FAK), which regulate
migration and matrix remodeling by endothelial cells [71]. This resulted in increased invasion
through collagen and fibrin gels, but also initiated neovascularization in vivo in the chorioallantoic
membrane of the chick embryo [71]. Additionally, Gremlin was found to be accumulated on lung
cancer-associated endothelial cells compared to a normal lung vasculature [71]. These findings
were later found to be caused by binding of Gremlin to the VEGF receptor 2 [72,73]. Interestingly,
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monomeric Gremlin showed the opposite effect by acting as a VEGF receptor 2 antagonist [74]. These
results suggest that dimeric Gremlin could directly and BMP independently support tumor growth by
promoting the “angiogenic switch” facilitating the generation of an endothelial network to provide the
cancerous cells with oxygen and a route by which they can metastasize. This could also explain the
tumor-promoting effects observed in studies utilizing overexpression models with supraphysiologic
levels of Gremlin. Interestingly, if Gremlin is indeed causally involved in increased angiogenesis within
tumors, monomeric Gremlin could be a novel therapeutic strategy to prevent neo-vascularization.
This was recently demonstrated in a study showing that monomeric Gremlin had an inhibiting effect
on the angiogenic and tumorigenic potential of murine prostate and breast cancer cells in vivo [74].
4.4. The Immune Cells
Immune cells comprise an important part of the tumor microenvironment influencing all stages
of cancer development and progression. Since many cells in the microenvironment respond to BMP
signaling, one would expect this for immune cells as well. Indeed, BMP signaling is found to be
implicated in CD4 T-cell homeostasis and activation [75,76], natural killer (NK) cell development [77],
chemotaxis of monocytes [78] and activation of programmed death-ligand 1 (PD-L1) and PD-L2
expression by dendritic cells [79,80]. Unfortunately, there is hardly any data on how BMP antagonists
affect the immune cells in the tumor microenvironment. In other, mostly inflammatory, diseases such
as fibrosis, arthritis and atherosclerosis, studies have been performed with potential implications for
cancer as well [81]. Below we will discuss these studies in more detail.
4.4.1. Gremlin
Multiple studies have described that binding of Gremlin to the VEGF receptor 2 on endothelial
cells, next to inducing angiogenesis, also evokes a proinflammatory response that leads to the induction
of several chemokines and cell adhesion molecules. Consequently, increased leukocyte adhesion and
extravasation is observed [82,83]. These authors also showed in a mouse xenograft experiment that
the presence of Gremlin expressing MCF7 breast cancer cells caused a significant increase of CD45+
cells, consisting of primarily F4/80+ macrophages, compared to mock-transfected MCF7 cells [83].
Besides inducing a proinflammatory response in endothelial cells, a recent study showed that Gremlin
activates the Notch pathway that is linked to renal inflammation in chronic kidney disease [84].
If Gremlin can indeed provoke a proinflammatory response that promotes the influx of F4/80+ cells,
the outcome would be highly dependent on the subtype of macrophage that is being recruited. While
the M1-macrophage is considered to exert favorable pro-inflammatory behavior, the M2-macrophage
is thought to be anti-inflammatory and could prevent an anti-tumor immune reaction. However,
data from two other studies suggest that Gremlin functions as an inhibitor of monocyte/macrophage
attraction [85,86]. In conclusion, more research is needed to better understand the effect of Gremlin on
immune cells in the tumor.
4.4.2. Noggin
The involvement of Noggin in immunomodulation is even less well studied with only a few
articles reporting an effect on immune cells. In a study on rheumatoid arthritis, the researchers
showed in the methylated bovine serum albumin (mBSA)-induced arthritis mouse model that Noggin
haploinsufficient (Noggin+/LacZ) mice had an increased number of CD4+ lymphocytes in their synovial
fluid compared to wild type mice [87]. Noggin was additionally shown to decrease the expression
of inflammatory factors in the vascular wall of mice from the diabetic db/db mouse model often used
for atherosclerosis research [88]. If Noggin can indeed counteract the recruitment of CD4 T-cells and
lower the expression of inflammatory factors, this would mean that Noggin counteracts inflammation.
Noggin probably exerts its effects by binding BMPs since BMP2 and BMP4 are implicated in being
involved in vascular inflammation [88]. The suppression of an inflammatory reaction is an undesirable
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property in established cancers, as an inflammatory response against cancer cells has been shown to
predict positive clinical outcomes in solid tumors [89].
5. Conclusions
With multiple studies reporting opposing effects of BMP antagonists, clearly much remains to
be deciphered and we still do not fully understand their multifaceted effects. Despite the increasing
awareness for the role of the BMP pathway in oncogenesis, very little research has been conducted
on understanding how the different cell types within the tumor contribute to this complex signaling
interplay. In this review we have discussed several studies that demonstrate a role for BMP antagonists
in the microenvironment in addition to their effect on the cancer cells. Unfortunately, many of these
results seem largely circumstantial. More research is needed to truly understand how BMPs and
BMP antagonists carry out their effects. We hypothesize that the effect is coherent with a (non-)
functional BMP signaling pathway within the cancer cells and that these cancer cells instruct their
microenvironment to secrete factors, either BMPs or BMP antagonists, to allow tumor growth. A better
understating of the role of BMP antagonists in cancer progression would be valuable as it could
potentially provide novel therapeutic strategies for many cancer types.
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